INO If the FDA grants priority review, a decision could arrive within six months of submission, potentially by late 2025 or early 2026. However, FDA approval is not guaranteed and depends on comprehensive clinical data and regulatory evaluation. INO-3107's BLA submission is planned for mid-2025, with potential approval by late 2025 or early 2026, pending regulatory review
INO supper risky but have a chance getting approve product by FDA, crazy how shaking hands here and dropped a lot, something fishy here ... if get approve this will be a big deal for sure and now undervalued stock, the fact is this can be 100 dollars up prices just makes riskier, I keep on eye this stock and news for sure
INO Oppenheimer was doing predictions on non-split price. The true predictions are: $30 (April 1st 2024) and $47(September 30 2024) - Assuming Market remains stable and company continues high performance.
INO If the FDA grants priority review, a decision could arrive within six months of submission, potentially by late 2025 or early 2026. However, FDA approval is not guaranteed and depends on comprehensive clinical data and regulatory evaluation. INO-3107's BLA submission is planned for mid-2025, with potential approval by late 2025 or early 2026, pending regulatory review